Since those ACC/AHA 2013 guidelines, a large- scale RCT in a racially/ethnically diverse population confirmed statin benefit from a moderate-inten- sity dose of a statin as compared with placebo in intermediate-risk patients. That RCT enrolled men 55 years of age and women 65 years of age with at least 1 cardiovascular risk factor. In the placebo group, the 10-year risk of hard ASCVD was 8.7%, and the risk of the expanded ASCVD endpoint that included coronary revascularization After 5.6 years, those assigned to rosuvastatin 10 mg/d demonstrated signifi- cant ARR in both co-primary endpoints with an acceptable safety record. By comparison, after a median follow-up of 1.9 years, those assigned a high-intensity dose of rosuvastatin in the JUPITER RCT achieved greater LDL-C-lowering and greater reductions in ASCVD outcomes. This corroborates meta-analyses demonstrating increased net ben- efit of evidence-based LDL-C lowering therapy in those at risk if greater reductions in LDL-C are 2. If in the context of a risk discussion, maximal ASCVD risk reduction is desired, it is reasonable to use a high-intensity statin to lower LDL-C by 50%. This provides increased benefit, espe- cially when 10-year ASCVD risk is 20%. JUPITER enrolled men 50 years of age and women 60 years of age with high-sensitivity C-reactive protein values 2.0 mg/L. Participants randomly assigned to 20 mg/d of rosuvastatin achieved median reductions in LDL-C of 50% and highly significant ASCVD risk reduction at 1.9 years.S4.4.2-6 The trial was stopped prematurely because of a highly significant reduction in cardiovascular death. However, wide individual variability in per- cent LDL-C reduction was noted. 